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Abstract  
Introduction: Management of seriously ill patients infected with new corona virus (SARS-CoV-2) is 
challenging especially in pregnancy and postpartum state. 
Case presentation: A 39- year-old primigravid critically ill woman with acute respiratory distress (ARDS) due 
to confirmed SARS-CoV-2 infection underwent urgent cesarean delivery (a healthy neonate) at 33 weeks and 
5/7 of pregnancy. She received treatments including hydroxychloroquine, antivirals and broad-spectrum 
antibiotics while she was intubated for mechanical ventilation. In spite of all treatments, she developed a 
critical course after the mild primary clinical improvement. Convalescent plasma transfusion as a rescue 
treatment was performed and led to an improvement in her general condition and delayed gradual recovery 
in respiratory function after two months. 
Conclusion: The promising role of early treatment with convalescent plasma transfusion in seriously ill 
pregnant women infected with SARS-CoV-2, needs to be elucidated by further randomized studies.  
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INTRODUCTION
The new corona virus is known as "Severe Acute 
Respiratory Syndrome Corona Virus 2 (SARS-CoV-
2)", responsible for COVID-19 disease originated in 
China and rapidly becomes a pandemic. Pregnant 
women are suggested to be at special risk with 
regard to  attenuating immune system and are 
proposed to be at increased risk of adverse 
outcome (1). Management of seriously ill patients 
infected with new corona virus (SARS-CoV-2) is 
challenging especially in pregnancy and postpartum 
state. Multiple investigational agents have been 
introduced for critically ill patients with partial 
clinical response in most cases (2).  
Convalescent plasma transfusion (CPT) containing 
antibodies of recovered patients has been reported 
to be promisingly responsive in the management of 
80 Chinese patients with SARS pneumonia in 2003 
(3). Although there are debates and concerns, the 
Food and Drug Administration (FDA) has approved 
this treatment for severe or life threatening cases 
with COVID -19 (4).  
We presented a seriously ill COVID-19 infected 
pregnant patient with acute respiratory distress 
syndrome (ARDS) with supportive care and CPT. 
CASE PRESENTATION  
A 39-year-old primigravid otherwise healthy 
Iranian woman at 33 and 5/7 weeks of pregnancy 
was admitted to the hospital with complaints of 
dyspnea, fever and dry cough for 4 days. At 
presentation, she was ill and febrile (oral 
temperature: 38.8 °C), hypoxemic (hemoglobin O2 
saturation (SPaO2) of 88% on room air) with 
respiratory rate of 33/minute, stable blood 
pressure (130/80 mmHg) and tachycardia (heart 
rate:100 bpm).  
Due to sepsis, fetal tachycardia (fetal heart rate: 
170 bpm), breech presentation of the fetus, and 
concern for deterioration of patient’s condition, the 
patient underwent an urgent cesarean delivery 
with spinal anesthesia under O2 therapy via face 
mask and while receiving first dose of antibiotics. A 
healthy neonate with an Apgar score of 7 in 5 
minutes and negative pharyngeal sample for SARS-
CoV-2 (taken just after delivery) was born.  
Several hours after delivery, she was transferred to 
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the intensive care unit (ICU) due to persistent 
hypoxemia (SPaO2 of 60%) and severe respiratory 
distress, and underwent intubation with 
mechanical ventilation support (system mode: 
SIMV, FIO2:100%, rate:22/min, TV:300 ml, SPaO2 
of 91%). Standard ICU care and prophylactic dose 
of enoxaparin were initiated. Due to a high clinical 
suspicion for COVID-19, lymphopenia and 
presence of multiple patchy ground glass opacities 
compatible with viral pneumonia on the lung 
computed tomography (CT) scan that was taken 
after intubation (figure 1), four drug regimens with 
hydroxychloroquine, Lopinavir /ritonavir, 
oseltamivir, and ribavirin were initiated based on 
that time guidelines of health ministry.  
Wide spectrum antibiotics including azithromycin, 
levofloxacin, vancomycin and meropenem were 
administered sequentially due to poor clinical 
response, severe ARDS, persistent elevated 
inflammatory markers and significant leukocytosis 
with possible bacterial super infection, while 
nasopharyngeal swab for SARS-CoV-2 was 
reported to be positive (taken at admission). Fever, 
agitation, PaO2/FIO2<200, mild leukocytosis, 
progressive lymphopenia, rising lactate 
dehydrogenase (LDH), elevated C-reactive protein 
(CRP), and erythrocyte sedimentation rate (ESR) 
despite normal procalcitonin, normal liver 
enzymes and renal function were evident during 
the first week of admission. On hospital day (HD) 8, 
patient showed some clinical improvement, 
became afebrile and fully conscious, with SPaO2 of 
93% on FIO2 sets at 60%. Soon after, she 
experienced deterioration in the clinical status 
 
Figure 1: A mid thoracic slice of chest HRCT scan with multiple patchy ground glass infiltrations and small bilateral pleural effusion 
at admission. 
 
Figure 2: Timeline of disease course according to days from hospital admission. (CPR: cardiopulmonary resuscitation; CPT: 
convalescent plasma therapy) 
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with recurring fever, agitation, requiring frequent 
administration of sedatives, persistent hypoxemia 
on 90-100% of FIO2 and some episodes of 
bradycardia. She finally developed asystole 
requiring cardiopulmonary resuscitation for 10 
min on HD 12 (figure 2). Echocardiography 
performed three hours after resuscitation, showed 
preserved right and left ventricular systolic 
functions. 
After that, she developed a critical course with 
fluctuating body temperature, escalating LDH 
levels and leukocyte counts, progressive 
lymphopenia and persistent low PaO2/FIO2, 
despite a full supportive ICU care and two pulses of 
methyl prednisolone followed by intravenous 
hydrocortisone in divided doses. Given her clinical 
deterioration, convalescent plasma transfusion, as 
a rescue treatment was decided to be infused after 
written informed consent was obtained from the 
patient and her family. 
A suitable candidate for plasma donation was 
selected based on approved criteria (approval ID 
project: IR.TMI.REC.1398.031). Eventually 1500cc 
of CPT was performed in three sessions on HD21, 
29 and 32 (figure 2).  
She did not experience any transfusion reaction or 
adverse events during the three CPT. Together with 
the clinical improvement, resolving of fever, 
gradual increase in PaO2/FIO2, laboratory results 
showed a decrease in the leukocytosis, the 
acceptable lymphocyte count and a constant 
decrease of in LDH, CPK, ESR and CRP levels after 
episodes of plasma infusion with no meaningful 
changes in serum ferritin, total immunoglobulin G 
(IgG) and interleukin 6 (IL-6) levels (table1). 
Packed red cells were transfused in four sessions 
for severe anemia (hemoglobin <7mg/dl) and 
pirfenidone as an anti-inflammatory and 
antifibrotic agent was started. Under full ICU care, 
after a period of fluctuations in PaO2/FIO2, she 
experienced the clinical and cognitive 
improvement and extubation on HD 70 and finally 
discharged on HD 88 on supportive oxygen 
therapy.  
DISCUSSION 
Considering pregnancy as an immune-
compromised state, implementing specific well-
defined strategies and a multidisciplinary 
approach for management of COVID-19 in 


























































































































Fever (°C) <37.3 38.8 38.5 37.6 37 37.3 37.1 37.2 37 36.5 36.7 37 37.1 
Consciousness - C A A C C C C C C A A C 




3.9- 11.1 11.2 23.2 10.4 7.5 9.2 13.1 16.7 12.6 7300 11 8.4 7.2 
Absolute 
neutrophil 
count (per µL) 
- 9968 20603 8008 6315 6624 11528 14028 10478 5800 8954 5462 4896 
Absolute 
lymphocyte 
count (per µL) 
- 985 1322 1248 1050 1472 1074 1319 1441 1390 1551 2063 1749 
Hemoglobin 
(g/dl) 
11.6- 15.3 11.5 11.5 9.6 9.7 8.9 9.1 9.5 7.7 9.3 8.7 9.3 8.6 
Hematocrit (%) 34- 46 33.7 37.7 31.4 31.4 28.5 31.2 30.5 25.3 31.3 27.2 29.1 25.9 
Platelet count 
(×103per µL) 
155- 440 176 286 217 188 213 289 217 189 193 161 431 234 
LDH (U/L) 207- 414 560 2215 1653 1118 1123 1411 2140 1849 1100 864 - - 
Procalcitonin 
(ng/ml) 
<0.5 0.1 0.52 0.3 0.09 - 0.3 -  - - - - 
CRP (mg/L) <5 10 11.2 9.3 10 10.3 10.1 10.7 9.8 7 18.2 7.3 19 
ESR 1sth hour 
(mm/hour) 
Up to 20 120 118 98 - - 96 101 92 78 - - - 
Interleukin-6 
(pg/ml) 
<0.5 - 8.1 14.9 - - 36.8 - - - - - - 
Ferritin(ng/ml) <5.9 - 633 493 - - 766 - - - - -  
IgG (mg/dl) 5-148 - 1160 1057 - - 818 - - - - -  
C: Conscious; A: Agitated; HD: hospital day; CPT: convalescent plasma therapy; IgG: immune globin G 
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obstetrics is highly recommended (5, 6). In a meta-
analysis on 192 articles about COVID-19 in 
pregnancy, ICU admission, invasive ventilation and 
extracorporeal membrane oxygenation (ECMO) 
were more common in pregnant as compared with  
age-matched non-pregnant women with overall 
339 death between 41664 women (1). Neutralizing 
antibody may suppress viremia via facilitating the 
clearance of the virus and reducing viral invasion 
to the host specific cells. The peak of viremia occurs 
in the first week of infection while the host immune 
response has a delay. It is suggested that better 
results may be obtained with early plasma 
transfusion (7). Eligible patients for CPT based on 
the FDA recommendation are those with confirmed 
COVID-19 exhibiting serious disease as" dyspnea, 
respiratory rate ≥ 30/min, SaO2 ≤ 93%, PaO2/FIO2 
< 300, and/or infiltrations in more than half of the 
lung fields" or patients with life-threatening signs 
including "respiratory failure, septic shock, and/or 
multiple organ dysfunction" (4). CPT in a seriously 
ill post-partum woman with ARDS and septic shock 
due to SARS-CoV2 infection was reported recently 
by Zhang B et al with favorable clinical outcome. In 
their study, postpartum patient underwent ECMO 
and continuous renal replacement therapy (CRRT) 
on HD 6. Convalescent plasma was transfused on 
HD 19 with extubation on HD40 and patient 
discharge on HD 46 (8). CPT has been used as a 
successful treatment, combined with 
corticosteroid for a midterm pregnant woman in 
our center (9). The case of this study, presented at 
beginning of the SARS-CoV-2 outbreak, without 
adequate evidence for COVID-19 treatments, 
became a candidate for CPT after failing most 
recommended drugs. Although promising results 
were achieved in her clinical condition based on 
blunting clinical severity, it seems that lung injury 
was more profound to respond to this immune 
therapy. Initiating this treatment earlier in the 
disease course may result in higher clinical benefits 
especially when the viral load is high as it was in 
this patient.  
CONCLUSIONS 
The promising role of early treatment with 
convalescent plasma transfusion in seriously ill 
pregnant women infected with SARS-CoV-2, needs 
to be elucidated by further randomized studies. 
Longstanding disease course with wax and wane 
respiratory function may be encountered in the 
clinical management of COVID-19. 
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